Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during the pandemic era,

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively.

Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various solid tumors.